PT-141 (Bremelanotide) Research: Melanocortin Receptor Agonism and Hypothalamic Pathways in Preclinical Models
PT-141 (Bremelanotide) is a cyclic melanocortin receptor agonist studied for MC3R/MC4R activation in hypothalamic circuits. Preclinical models document dose-dependent behavioral endpoints via dopaminergic and oxytocin pathways — distinct from PDE5 inhibitor mechanisms. Independent research compilation for scientific and educational reference only.
